Biography: Kumar Sharma, MD

Kumar Sharma, MD
  • Professor of Medicine
  • Director, Institute of Metabolomic Medicine
  • Center for Renal Translational Medicine
  • UC San Diego Health Sciences
  • San Diego, CA

Kumar Sharma, MD is Professor of Medicine at the University of California, San Diego and serves as the Director of the Institute for Metabolomic Medicine and the Center for Renal Translational Medicine. He is Founding Chair of the ISN Nexus Symposium Core Committee, an international translational symposium and has co-organized an NIH Mitochondrial Workshop and many international symposiums. He completed his MD and Internal Medicine residency at the Albert Einstein College of Medicine in New York and his clinical and research nephrology fellowship was completed at the University of Pennsylvania. His research has been continuously funded by the NIDDK, JDRF and the ADA. Dr. Sharma has had a dedicated and consistent translational approach for diabetic complications for the past 25 years and has expertise in developing phenotype analysis using imaging, molecular and biochemical methods, genomics, microarray, proteomics and metabolomics. He has over 150 peer-reviewed original and review articles in top-notch journals (Nature Medicine, Journal of Clinical Investigation, Cell Metabolism) and has been the recipient of several awards. His recent studies have employed novel imaging and systems biology approaches to understand novel mechanisms related to obesity-related complications, diabetic kidney disease and novel therapies. His major focus in the past few years has been to develop novel biomarkers for chronic kidney disease and diabetic complications. In particular, recent metabolomic and mitochondrial studies in animal models and humans have led to novel insights and new theories into the pathogenesis of diabetic complications and the role of the kidney in energy metabolism.

Dr. Sharma has maintained a strong clinical practice with a focus on patients with type 1 and type 2 diabetes and kidney disease. He has conducted NIH-funded and industry supported investigator-initated clinical trials. He has a major interest in the development of clinical biomarkers of kidney disease progression.